The forces reshaping the global oncology market — and what pharmaceutical companies, device manufacturers, cancer centre operators, and investors need to understand.

• Immuno-Oncology Expanding Into Earlier Lines of Therapy and Curative-Intent Settings: PD-1/PD-L1 checkpoint inhibitor combinations are advancing from metastatic settings into neoadjuvant and adjuvant curative-intent treatment neoadjuvant and adjuvant curative-intent treatment— pembrolizumab approvals in early-stage NSCLC, TNBC, bladder, and melanoma are expanding the checkpoint inhibitor treatment population from advanced disease to the much larger early-stage patient population, significantly expanding immuno-oncology market size beyond the addressable metastatic disease population.
• ADC Pipeline Maturation Establishing a New Standard-of-Care Category Across Multiple Tumour Types: Antibody-drug conjugate approvals across HER2-positive and HER2-low breast cancer (T-DXd T-DXd), urothelial carcinoma (enfortumab vedotin), cervical cancer (tisotumab vedotin), and NSCLC are establishing ADCs as a distinct and rapidly growing therapeutic class — with over 100 ADCs in clinical development targeting an expanding range of tumour-associated antigens.
• Bispecific Antibody Approvals in Haematological Malignancies Signalling Broader Solid Tumour Pipeline Expansion: Blinatumomab, teclistamab, mosunetuzumab, and glofitamab approvals in ALL, multiple myeloma, and diffuse large B-cell lymphoma are establishing bispecific antibodies as the standard-of-care in relapsed/refractory haematological malignancies — with a large and advancing solid tumour bispecific antibody pipeline targeting lung, breast, colorectal, and prostate cancer.
• Radioligand Therapy Emerging as a High-Value Oncology Therapeutic Modality Beyond PSMA Prostate Cancer: Lutetium-177 PSMA-617 approval in metastatic castration-resistant prostate cancer is catalysing radioligand therapy programme investment radioligand therapy programme investmentacross neuroendocrine tumours, breast cancer, lung cancer, and other solid tumour types — with Novartis, Bayer, Bristol Myers Squibb, and emerging biotech companies advancing radioligand therapy programmes targeting novel ligands and isotope combinations beyond first-generation prostate cancer applications.
• AI-Powered Oncology Diagnostics Improving Early Detection and Treatment Selection at Scale: AI-assisted mammography, lung CT screening analysis, pathology image analysis, and liquid biopsy multi-cancer early detection liquid biopsy multi-cancer early detectionare demonstrating clinically meaningful improvements in early cancer detection sensitivity — with AI diagnostic tools beginning to transition from academic validation to broad clinical deployment in screening programmes across the US, Europe, and Asia Pacific, driving early-stage diagnosis that expands curative-intent treatment opportunities.
• Emerging Market Cancer Care Infrastructure Investment Expanding the Global Treatment-Eligible Population: Cancer care infrastructure investment across China, India, the Middle East, and Southeast Asia is expanding the population of cancer patients with access to standard-of-care oncology treatment — China’s NMPA oncology drug approval acceleration national cancer centre network expansion China’s NMPA oncology drug approval acceleration national cancer centre network expansion, India’s Ayushman Bharat oncology coverage expansion, and GCC comprehensive cancer centre development are the largest emerging market oncology infrastructure programmes driving diagnosis and treatment volume growth.